[go: up one dir, main page]

MX2019005533A - Tratamiento de la fibrosis. - Google Patents

Tratamiento de la fibrosis.

Info

Publication number
MX2019005533A
MX2019005533A MX2019005533A MX2019005533A MX2019005533A MX 2019005533 A MX2019005533 A MX 2019005533A MX 2019005533 A MX2019005533 A MX 2019005533A MX 2019005533 A MX2019005533 A MX 2019005533A MX 2019005533 A MX2019005533 A MX 2019005533A
Authority
MX
Mexico
Prior art keywords
treatment
fibrosis
hepato
inhibition
fibrotic
Prior art date
Application number
MX2019005533A
Other languages
English (en)
Inventor
Gorfine Tali
Hayardeny-Nissimoiv Liat
Baharaff Allen
M Mato De La Paz Jose
Original Assignee
Galmed Res And Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galmed Res And Development Ltd filed Critical Galmed Res And Development Ltd
Publication of MX2019005533A publication Critical patent/MX2019005533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al tratamiento y reducción de la fibrosis, incluyendo fibrosis hepática Más especificamente, las modalidades de la invención proporcionan composiciones y métodos útiles para el tratamiento e inhibición de trastornos fibróboos, afecciones hepatofibróticas asociadas con la Enfermedad de Ácido Graso No Alcohólico (NAF ID) y Esteatohepahtis No Alcohólica (NASH), empleando el uso de ácido 3A-araquichlamido-7o,12o-dihidro xi-511.colan-24-oico (Aramcho), o una sal farmacéuticamente aceptable del mismo. En otras modalidades. se contempla el tratamiento e inhibición de afecciones hepatofibiótcas causadas por contacto con sustancias químicas hepatotóxicas o por obstrucción mecánica.
MX2019005533A 2016-11-10 2017-11-10 Tratamiento de la fibrosis. MX2019005533A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662420009P 2016-11-10 2016-11-10
US201662420017P 2016-11-10 2016-11-10
US201662420012P 2016-11-10 2016-11-10
US201762475129P 2017-03-22 2017-03-22
PCT/IB2017/001521 WO2018087599A1 (en) 2016-11-10 2017-11-10 Treatment for fibrosis

Publications (1)

Publication Number Publication Date
MX2019005533A true MX2019005533A (es) 2020-02-07

Family

ID=62109644

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005533A MX2019005533A (es) 2016-11-10 2017-11-10 Tratamiento de la fibrosis.

Country Status (10)

Country Link
EP (1) EP3538158B1 (es)
JP (2) JP7369033B2 (es)
KR (2) KR20210042421A (es)
CN (1) CN110191724A (es)
AU (2) AU2017357867B2 (es)
CA (3) CA3226066A1 (es)
IL (3) IL266530B2 (es)
MA (2) MA46788A (es)
MX (1) MX2019005533A (es)
WO (1) WO2018087599A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
PL3730487T3 (pl) 2016-06-13 2022-08-16 Gilead Sciences, Inc. Pochodne azetydyny jako modulatory fxr (nr1h4)
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
WO2018193006A1 (en) * 2017-04-18 2018-10-25 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
US10624944B2 (en) * 2017-06-19 2020-04-21 Creative Bio-Peptides Inc. Anti-inflammatory peptides for treating non-alcoholic steatohepatitis (NASH)
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
WO2020095293A1 (en) * 2018-11-07 2020-05-14 Galmed Research And Development Ltd Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients
PE20211907A1 (es) 2019-01-15 2021-09-28 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
KR102538047B1 (ko) * 2020-03-11 2023-05-30 동아에스티 주식회사 비알콜성지방간염의 예방 또는 치료를 위한 약학적 조성물
US11319313B2 (en) * 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
SE544447C2 (en) * 2020-09-29 2022-05-31 Tx Medic Ab Treatment of fatty liver diseases
CN114470217B (zh) * 2020-11-24 2023-06-20 深圳微芯生物科技股份有限公司 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物
US20240325399A1 (en) * 2021-07-15 2024-10-03 Future Medicine Co., Ltd. Pharmaceutical composition for preventing or treating cholangitis or liver disease caused by cholangitis comprising adenosine derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2712617T1 (sl) * 2004-03-12 2017-01-31 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo Fxr ligandov
US8318708B2 (en) * 2007-11-06 2012-11-27 Salk Institute For Biological Studies Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis
BR112017014341A2 (pt) * 2015-01-09 2018-03-27 Gilead Apollo, Llc método e sistema para tratamento, estabilização, ou redução da gravidade ou progressão de uma doença de fígado gorduroso não alcoólica, e, composição.
WO2017017677A1 (en) * 2015-07-27 2017-02-02 Galmed Research And Development Ltd. Combination treatment for liver disease
EP3463350B1 (en) * 2016-06-03 2023-09-13 ChemoCentryx, Inc. Pyrrolo-pyridines and pyrrolo-pyrimidines for use in treating liver fibrosis

Also Published As

Publication number Publication date
IL311409A (en) 2024-05-01
AU2023285907A1 (en) 2024-02-01
BR112019009516A2 (pt) 2019-07-30
IL266530A (en) 2019-07-31
CA3152584A1 (en) 2018-05-17
KR20210042421A (ko) 2021-04-19
JP7369033B2 (ja) 2023-10-25
JP2021178863A (ja) 2021-11-18
JP2019534311A (ja) 2019-11-28
AU2017357867A1 (en) 2019-06-27
IL266530B2 (en) 2024-09-01
IL266530B1 (en) 2024-05-01
CA3152584C (en) 2024-02-13
CA3043284C (en) 2022-06-28
JP7313405B2 (ja) 2023-07-24
CA3043284A1 (en) 2018-05-17
IL309558A (en) 2024-02-01
KR20190083659A (ko) 2019-07-12
EP3538158B1 (en) 2023-11-01
MA47558A (fr) 2019-09-18
EP3538158A1 (en) 2019-09-18
AU2017357867B2 (en) 2023-12-14
CN110191724A (zh) 2019-08-30
CA3226066A1 (en) 2018-05-17
MA46788A (fr) 2019-09-18
WO2018087599A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
MX2019005533A (es) Tratamiento de la fibrosis.
MY209138A (en) Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
MY189770A (en) Biaryl derivative as gpr120 agonists
HRP20192299T1 (hr) Liječenje nafld i nash
WO2015101957A3 (en) Inhibitors of glutaminase
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
IL232267A (en) Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective
MX360979B (es) Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
HK1232147A1 (zh) 用於治疗纤维化的赛尼克韦罗
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
CO2020001702A2 (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
WO2017053868A8 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
MX2014002492A (es) Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida.
HK1217092A1 (zh) 治疗性化合物及其用途
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
BR112016024020A2 (pt) composição farmacêutica
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MY179783A (en) Substituted bicyclic compounds
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
BR112015019776A2 (pt) comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos